Next Article in Journal
Molecular Mechanisms Underlying Yatein-Induced Cell-Cycle Arrest and Microtubule Destabilization in Human Lung Adenocarcinoma Cells
Previous Article in Journal
Radioiodine-Refractory Thyroid Cancer: Molecular Basis of Redifferentiation Therapies, Management, and Novel Therapies
Open AccessArticle

Encapsulated Carbenoxolone Reduces Lung Metastases

The Institute for Drug Research, The School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, 9112102 Jerusalem, Israel
Department of Cell Biology and Cancer Science, The Ruth and Bruce Rappaport Faculty of Medicine, Technion—Israel Institute of Technology, Efron 1, 3535422 Haifa, Israel
The Institute of Pulmonary Medicine at Hadassah-Hebrew University Medical Center, 9112102 Jerusalem, Israel
Author to whom correspondence should be addressed.
Cancers 2019, 11(9), 1383;
Received: 11 July 2019 / Revised: 23 August 2019 / Accepted: 9 September 2019 / Published: 17 September 2019
Carbenoxolone is an anti-inflammatory compound and a derivate of a natural substance from the licorice plant. We previously showed that carbenoxolone reduces the metastatic burden in the lungs of mice through its antagonistic effect on high mobility group box 1 (HMGB1). To further enhance carbenoxolone’s activity and localization in the lungs, thereby reducing the potential adverse side effects resulting from systemic exposure, we developed a poly(lactic-co-glycolic acid) (PLGA) slow-release system for pulmonary delivery which maintains drug activity in-vitro, as demonstrated in the anoikis assay. Both systemic and intranasal administrations of carbenoxolone effectively minimize metastatic formation in a lung colonization model in mice. Our results show a decrease in the metastatic burden in the lung tissue. Notably, the therapeutic effect of a single intranasal administration of 25 mg/kg carbenoxolone, in the form of drug-loaded particles, had a similar effect in reducing metastatic lesions in the lungs to that of a 10-fold dose of the free drug via intraperitoneal injections, three times per week over the course of four weeks. These data offer new means to potentiate the anti-cancer activity of carbenoxolone and simultaneously reduce the requirement for high dosage administration; the upshot substantially improves therapeutic effect and avoidance of side effects. View Full-Text
Keywords: cancer; carbenoxolone; lungs; metastases; particles; drug delivery; double emulsion; intranasal administration cancer; carbenoxolone; lungs; metastases; particles; drug delivery; double emulsion; intranasal administration
Show Figures

Figure 1

MDPI and ACS Style

Karsch-Bluman, A.; Avraham, S.; Assayag, M.; Schwob, O.; Benny, O. Encapsulated Carbenoxolone Reduces Lung Metastases. Cancers 2019, 11, 1383.

AMA Style

Karsch-Bluman A, Avraham S, Assayag M, Schwob O, Benny O. Encapsulated Carbenoxolone Reduces Lung Metastases. Cancers. 2019; 11(9):1383.

Chicago/Turabian Style

Karsch-Bluman, Adi; Avraham, Shimrit; Assayag, Miri; Schwob, Ouri; Benny, Ofra. 2019. "Encapsulated Carbenoxolone Reduces Lung Metastases" Cancers 11, no. 9: 1383.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop